Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for
the Treatment of Obesity at the American Diabetes Association 67th
Scientific Session
PLYMOUTH MEETING, Pa., June 25, 2007 /PRNewswire-FirstCall/ --Genaera Corporation today announced that data from a preclinicalstudy of
trodusquemine (MSI-1436) for the treatment of obesity werepresented during the American Diabetes Association (ADA) 67thScientific Sessions, June 22-25 in Chicago, IL. Dr. Kristen Lantz,Genaera research scientist and lead author of Abstract #1801-P,present...
Genaera to Present Preclinical Data on Trodusquemine for the
Treatment of Obesity at the American Diabetes Association 67th
Scientific Sessions
PLYMOUTH MEETING, Pa., June 19, 2007 /PRNewswire-FirstCall/ --Genaera Corporation today announced that it will present a posteron
trodusquemine (MSI-1436), its novel anti-obesity compound,during the American Diabetes Association (ADA) 67th ScientificSessions, June 22 to 25 in Chicago. The abstract, # 1801-P, is titled, "
Trodusquemine is a MultiplePathway Inhibitor that Causes Diffe...